MarketPeel
Insider Trading Intelligence
BM

Briggs Morrison

SNDX
PRESIDENT, HEAD OF R&D · SYNDAX PHARMACEUTICALS INC · CIK 0001654430
FILING MIX · LIFETIME49%/51%
BUYS
55
SELLS
57
TOTAL VALUE
$42.20M
COMPANIES
5
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
200,634
AVG SELL PX
$23.08
TRADE KIND
SHOWING 112 / 112
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
35 backtested trades · 8 horizons · 5 pending
Forward-return performance of every backtestable P/S trade by Briggs Morrison, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d35+71.43%-0.06%-0.95%+0.89%+0.56%0.85
14d35+48.57%+0.52%-1.67%+2.19%+2.65%1.44
30d35+65.71%-0.20%-2.14%+1.95%+3.72%0.77
60d35+80.00%-7.89%-0.88%-7.01%-8.80%-2.52
90d35+57.14%-1.40%-1.03%+0.86%-1.71%0.20
180d35(1 pending)+79.41%-8.81%-1.65%-7.16%-9.11%-1.31
1y35(2 pending)+63.64%-8.82%+10.08%-18.90%-37.06%-3.14
2y35(2 pending)+75.76%-13.73%+30.02%-43.74%-48.39%-6.55
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SNDX · 34,836 shares · as of Feb 7, 2024
048,75097,500146,250195,0002021202220232024SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 55 buys / 57 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
15,527111,548Jun 24, 2026Jun 26, 2026View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
22,71422,714Jun 24, 2026Jun 26, 2026View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
13,00013,000Jun 5, 2026Jun 9, 2026View →
ARVN
ARVINAS, INC.
PURCHASE
20,000$13.40$268.1K96,021Mar 6, 2026Mar 9, 2026View →
ARVN
ARVINAS, INC.
PURCHASE
30,000$7.57$227.0K76,021Sep 22, 2025Sep 24, 2025View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
23,10523,105Jun 25, 2025Jun 27, 2025View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
16,02546,021Jun 25, 2025Jun 27, 2025View →
HOWL
WEREWOLF THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
27,00027,000Jun 12, 2025Jun 13, 2025View →
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
13,00013,000Jun 5, 2025Jun 6, 2025View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
9,0709,070May 29, 2024May 31, 2024View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
5,89929,996May 29, 2024May 31, 2024View →
HOWL
WEREWOLF THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
17,50017,500May 24, 2024May 24, 2024View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
17,00034,836Feb 7, 2024Feb 9, 2024View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE10b5-1
10b5-1 plan
52,855$18.27$965.4K17,836Aug 9, 2023Aug 10, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
52,8550Aug 9, 2023Aug 10, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
52,855$8.77$463.5K70,691Aug 9, 2023Aug 10, 2023View →
HOWL
WEREWOLF THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,20013,200Jun 21, 2023Jun 23, 2023View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
12,78712,787Jun 15, 2023Jun 20, 2023View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
4,12124,097Jun 15, 2023Jun 20, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
24,5820Jun 9, 2023Jun 9, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
28,2730Jun 9, 2023Jun 9, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
24,582$6.38$156.8K42,418Jun 9, 2023Jun 9, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
28,273$8.77$248.0K70,691Jun 9, 2023Jun 9, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE10b5-1
10b5-1 plan
28,273$21.18$598.8K17,836Jun 9, 2023Jun 9, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE10b5-1
10b5-1 plan
24,582$21.18$520.6K46,109Jun 9, 2023Jun 9, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
52,8550May 9, 2023May 10, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE10b5-1
10b5-1 plan
52,855$21.41$1.13M17,836May 9, 2023May 10, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
52,855$6.38$337.2K70,691May 9, 2023May 10, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE10b5-1
10b5-1 plan
52,855$19.53$1.03M17,836Apr 10, 2023Apr 12, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
52,8550Apr 10, 2023Apr 12, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
52,855$6.38$337.2K70,691Apr 10, 2023Apr 12, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
52,854$22.53$1.19M17,836Mar 13, 2023Mar 14, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
52,8540Mar 13, 2023Mar 14, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
President, Head of R&D
52,854$6.38$337.2K70,690Mar 13, 2023Mar 14, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
52,8540Feb 6, 2023Feb 8, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
52,854$26.83$1.42M17,836Feb 6, 2023Feb 8, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
President, Head of R&D
52,854$6.38$337.2K70,690Feb 6, 2023Feb 8, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
32,000$28.55$913.6K32,000Feb 2, 2023Feb 3, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
President, Head of R&D
59,649$10.90$650.2K77,485Sep 20, 2022Sep 21, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
59,649$23.25$1.39M17,836Sep 20, 2022Sep 21, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
59,6490Sep 20, 2022Sep 21, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
114,339$23.03$2.63M17,836Sep 19, 2022Sep 21, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
114,3390Sep 19, 2022Sep 21, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
President, Head of R&D
114,339$10.90$1.25M132,175Sep 19, 2022Sep 21, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
71,966$23.22$1.67M17,836Sep 16, 2022Sep 16, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
President, Head of R&D
53,034$10.90$578.1K70,870Sep 16, 2022Sep 16, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
53,034$23.22$1.23M17,836Sep 16, 2022Sep 16, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
71,9660Sep 16, 2022Sep 16, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
53,0340Sep 16, 2022Sep 16, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
President, Head of R&D
71,966$7.20$518.2K89,802Sep 16, 2022Sep 16, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
66,775$24.20$1.62M17,836Sep 15, 2022Sep 16, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
President, Head of R&D
66,775$7.20$480.8K84,611Sep 15, 2022Sep 16, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
66,7750Sep 15, 2022Sep 16, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
87,645$23.80$2.09M17,836Sep 14, 2022Sep 16, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
87,6450Sep 14, 2022Sep 16, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
President, Head of R&D
87,645$7.20$631.0K105,481Sep 14, 2022Sep 16, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
President, Head of R&D
62,292$7.20$448.5K80,128Jul 1, 2022Jul 5, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
62,292$19.00$1.18M17,836Jul 1, 2022Jul 5, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
62,2920Jul 1, 2022Jul 5, 2022View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
10,19210,192Jun 16, 2022Jun 21, 2022View →
HOWL
WEREWOLF THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
11,60011,600Jun 1, 2022Jun 3, 2022View →
ARVN
ARVINAS, INC.
SALE
7,104$66.07$469.4K30,730Apr 14, 2022Apr 18, 2022View →
ARVN
ARVINAS, INC.
PURCHASE
16,188$16.00$259.0K40,936Apr 14, 2022Apr 18, 2022View →
ARVN
ARVINAS, INC.
SALE
16,188494Apr 14, 2022Apr 18, 2022View →
ARVN
ARVINAS, INC.
SALE
10,754$67.03$720.9K19,976Apr 14, 2022Apr 18, 2022View →
ARVN
ARVINAS, INC.
SALE
3,102$65.24$202.4K37,834Apr 14, 2022Apr 18, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
3,1280Apr 4, 2022Apr 13, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
3,1280Apr 4, 2022Apr 5, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
President, Head of R&D
3,128$10.90$34.1K20,964Apr 4, 2022Apr 5, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
3,128$18.29$57.2K17,836Apr 4, 2022Apr 5, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
President, Head of R&D
3,128$7.20$22.5K20,964Apr 4, 2022Apr 13, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
70,5450Apr 1, 2022Apr 13, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
24,500$17.44$427.3K17,836Apr 1, 2022Apr 5, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
President, Head of R&D
70,545$10.90$768.9K88,381Apr 1, 2022Apr 5, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
70,545$17.46$1.23M17,836Apr 1, 2022Apr 5, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
70,5450Apr 1, 2022Apr 5, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
President, Head of R&D
6,000$17.44$104.6K42,336Apr 1, 2022Apr 5, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
President, Head of R&D
70,545$7.20$507.9K88,381Apr 1, 2022Apr 13, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
160,000$15.79$2.53M160,000Feb 2, 2022Feb 3, 2022View →
ARVN
ARVINAS, INC.
PURCHASE
16,188$16.00$259.0K45,708Jan 14, 2022Jan 19, 2022View →
ARVN
ARVINAS, INC.
SALE
9,919$64.33$638.1K35,789Jan 14, 2022Jan 19, 2022View →
ARVN
ARVINAS, INC.
SALE
16,18816,682Jan 14, 2022Jan 19, 2022View →
ARVN
ARVINAS, INC.
SALE
2,108$67.69$142.7K24,748Jan 14, 2022Jan 19, 2022View →
ARVN
ARVINAS, INC.
SALE
5,100$67.28$343.1K26,856Jan 14, 2022Jan 19, 2022View →
ARVN
ARVINAS, INC.
SALE
3,833$65.24$250.1K31,956Jan 14, 2022Jan 19, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Executive Officer
35,156$20.00$703.1K48,336Dec 17, 2021Dec 20, 2021View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
35,156$10.90$383.2K83,492Dec 17, 2021Dec 20, 2021View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Executive Officer
35,1560Dec 17, 2021Dec 20, 2021View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Executive Officer
500Sep 20, 2021Sep 20, 2021View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
50$7.20$36048,386Sep 20, 2021Sep 20, 2021View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Executive Officer
50$20.00$1.0K48,336Sep 20, 2021Sep 20, 2021View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Executive Officer
70,2620Sep 17, 2021Sep 20, 2021View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Executive Officer
70,262$20.07$1.41M48,336Sep 17, 2021Sep 20, 2021View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
70,262$7.20$505.9K118,598Sep 17, 2021Sep 20, 2021View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
7,5117,511Jun 8, 2021Jun 10, 2021View →
HOWL
WEREWOLF THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
23,20023,200Apr 30, 2021May 4, 2021View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Executive Officer
35,156$20.55$722.4K48,336Feb 8, 2021Feb 10, 2021View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Executive Officer
35,1560Feb 8, 2021Feb 10, 2021View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
35,156$7.20$253.1K83,492Feb 8, 2021Feb 10, 2021View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
195,000195,000Feb 3, 2021Feb 5, 2021View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
1,771$12.00$21.3K48,336Jan 31, 2021Feb 5, 2021View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Executive Officer
17,466$20.06$350.3K46,565Nov 10, 2020Nov 12, 2020View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
17,466$7.20$125.8K64,031Nov 10, 2020Nov 12, 2020View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Executive Officer
17,4660Nov 10, 2020Nov 12, 2020View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Executive Officer
62,938$20.04$1.26M46,565Nov 9, 2020Nov 12, 2020View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
62,938$7.20$453.2K109,503Nov 9, 2020Nov 12, 2020View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Executive Officer
62,9380Nov 9, 2020Nov 12, 2020View →
NXTC
NEXTCURE, INC.
PURCHASEGRANT
Stock grant
14,25014,250Jun 11, 2020Jun 15, 2020View →
ARVN
ARVINAS, INC.
PURCHASEGRANT
Stock grant
12,00012,000Jun 3, 2020Jun 4, 2020View →
ARVN
ARVINAS, INC.
PURCHASE
2,500$38.18$95.5K29,520Mar 24, 2020Mar 25, 2020View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
194,000194,000Feb 12, 2020Feb 14, 2020View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
12,500$8.00$100.0K43,900Feb 4, 2020Feb 5, 2020View →
Other insiders · SNDX
Loading peer insiders…
About this filer
CIK 0001654430
ROLE
President, Head of R&D
PRIMARY
SNDX
COMPANIES
5
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001654430DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback